We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Impact of Body Weight on Pharmacokinetic Analysis of Doxorubicin + Cyclophosphamide in Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01542203
Recruitment Status : Unknown
Verified January 2012 by University of Texas Southwestern Medical Center.
Recruitment status was:  Not yet recruiting
First Posted : March 2, 2012
Last Update Posted : March 2, 2012
Information provided by (Responsible Party):

Study Description
Brief Summary:
This single site study will be conducted at the UT Southwestern Simmons Cancer Center. This study is designed to measure drug concentrations in the blood of 18 female breast cancer patients who require doxorubicin (30 minute infusion) and cyclophosphamide (30 minute infusion) as part of standard medical care. Up to a total of 40 adult female participants will be consented for the study at the cancer center. Eighteen of these participants are needed to complete the study. The others will likely be screen failures. The participants will have no more than 100 ml of blood drawn via a peripheral intravenous catheter just prior to the doxorubicin infusion, and then at 0.5, 1, 1.5, 2, 3, 4, 5, 12-24, and 24-72 h after the beginning of the doxorubicin infusion. The 5 hour blood draw is optional. The intravenous catheter will be removed when the participant is discharged from the cancer center on day 1. The participant will be asked to return to the cancer center at 12-24 and 24-72 hours to have the final 2 blood draws conducted. The participants must be treated with Doxorubicin and Cyclophosphamide in order to participate in this pharmacokinetic analysis study.

Condition or disease
Breast Cancer

Detailed Description:

The study will require a total of 11 participant contacts over 3 days (1 day outpatient clinic visit for doxorubicin and cyclophosphamide infusions and blood draws, 2 follow up outpatient clinic visits for blood draws) with no more than 100 mL of blood being drawn. All blood draws will be collected for the purpose of research.

Screening and Informed Consent Procedures

  1. The participant's height, weight, medical history, comorbid conditions, and current medications will be obtained from the electronic medical record (EMR).

    Update 1 : January 12, 2012

  2. Study personnel will provide the participant with additional information about the study and provide the participant with the opportunity to ask any questions. Each participant will then be asked if she is willing to provide informed consent.
  3. Information from the routine physical examination including vital signs (temperature,respiratory rate, blood pressure, heart rate) will be collected from the medical chart.

Procedures and Evaluation during the Research

  1. Each participant will then have no more than10ml of blood drawn 8 times, at t=0h (predose),at the end of the doxorubicin infusion, at the end cyclophosphamide infusion, and 1.5, 2, 3, 4, 5, 12-24, and 24-72 h following the beginning of doxorubicin infusion. All blood draws will be performed using the peripheral intravenous catheter being used for standard medical care. Labels on blood samples will not contain participant name, but a randomly generated participant identification number.
  2. All blood samples will placed on ice and immediately transported to Dr. Richard Leff's laboratory for sample preparation.9 Samples will be spun in a refrigerated centrifuge and then placed in a -80oC freezer. As explained below, Dr. Leff or his laboratory will not have access to any participant identifiers.
  3. The participant is discharged from the cancer center (for research purposes) after the 4 hour blood draw, unless the participant is willing to stay for the 5 hour blood draw.
  4. The participant will return to the cancer center at 12-24 and 24-72 hours for blood draws.
  5. The participant is discharged from the study after the 24-72h blood draw. Follow-up: Participants will be asked to return to the cancer center for 12-24 and 24-72 hour blood draws.

Study Design

Study Type : Observational
Estimated Enrollment : 18 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Impact of Body Weight on the Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide in Breast Cancer Patients
Study Start Date : March 2012

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Groups and Cohorts

Breast Cancer, Various BMIs
18 female breast cancer patients who are normal weight (body mass index [BMI] < 25 kg/m2, overweight or class I obese(BMI 25-34.9 kg/m2), or class II-III obese (BMI > 35 kg/m2).

Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
primary care clinic

Inclusion Criteria:

  • Females,
  • age 18 years of age or older, of all racial and ethnic origins that are scheduled to receive the first cycle of a single intravenous dose of doxorubicin (30 minute infusion) and cyclophosphamide (30 minute infusion) as part of standard medical care for breast cancer.
  • English and/or Spanish speaking participants are eligible to participate.

Exclusion Criteria:

  • Pregnant or nursing or unwilling to use a reliable contraception method during the study. The effects of doxorubicin and cyclophosphamide on pregnancy are unknown. In addition, the metabolic changes that accompany pregnancy may alter the concentration-time profile of doxorubicin or cyclophosphamide, so that the pregnancy and post-partum state would be a confounding variable.
  • Participants unwilling to comply with study procedures.
  • CrCl < 10 ml/min
  • Participants requiring peritoneal or hemodialysis
  • Serum bilirubin > 1.19 mg/dL
  • Receipt of the following drugs that:

    • Alter doxorubicin concentrations: carbamazepine, cyclosporine, fosphenytoin, paclitaxel, phenytoin, sorafenib, valspodar, verapamil
    • Alter cyclophosphamide concentrations: cyclosporine, nevirapine, ondansetron
    • All other drugs will be reviewed during screening of the patient
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01542203

Contact: Ronald Hall, PharmD 2146483200 Ron.Hall@UTSouthwestern.edu

United States, Texas
UTSouthwestern Medical Center Not yet recruiting
Dallas, Texas, United States, 75390
Contact: Ronald Hall, PharmD    214-648-7097    ron.hall@utsouthwestern.edu   
Sponsors and Collaborators
University of Texas Southwestern Medical Center
Texas Tech University Health Sciences Center
More Information

Responsible Party: University of Texas Southwestern Medical Center
ClinicalTrials.gov Identifier: NCT01542203     History of Changes
Other Study ID Numbers: STU 062011-056
First Posted: March 2, 2012    Key Record Dates
Last Update Posted: March 2, 2012
Last Verified: January 2012

Keywords provided by University of Texas Southwestern Medical Center:
Breast Cancer

Additional relevant MeSH terms:
Breast Neoplasms
Body Weight
Neoplasms by Site
Breast Diseases
Skin Diseases
Signs and Symptoms
Liposomal doxorubicin
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors